The invention relates to compounds capable of inhibiting the visual cycle and/or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular glaucoma, and other diseases of the retinal and/or optic nerve where an imbalance between metabolic demand and blood supply contribute to the development of tissue damage. The invention furthermore relates to pharmaceutical compositions comprising such compounds.
